[1]刘向华,陈媛.圣愈汤合增液汤联合化疗治疗Ki-67过表达卵巢癌的安全性分析[J].西部中医药,2018,31(04):93-95.
　LIU Xianghua,CHEN Yuan.Analysis of the Safety of ShengYuTang, ZengYeTang Combined with Chemotherapy in Treating Ki-67 Over-expression of Oophoroma[J].Western Journal of Traditional Chinese Medicine,2018,31(04):93-95.
点击复制

圣愈汤合增液汤联合化疗治疗Ki-67过表达卵巢癌的安全性分析()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年04期
页码:
93-95
栏目:
出版日期:
2018-04-15

文章信息/Info

Title:
Analysis of the Safety of ShengYuTang, ZengYeTang Combined with Chemotherapy in Treating Ki-67 Over-expression of Oophoroma
文章编号:
1004-6852(2018)04-0093-03
作者:
刘向华1，2' target="_blank" rel="external">2，陈媛1，2' target="_blank" rel="external">2
1 甘肃省酒泉肿瘤医院，甘肃 酒泉 735000；2 酒泉市第二人民医院
Author(s):
LIU Xianghua1,2' target="_blank" rel="external">2, CHEN Yuan1,2' target="_blank" rel="external">2
1 Gansu Provincial Jiuquan Cancer Hospital, Jiuquan 735000, China; 2 Jiuquan City People′s Hospital
关键词:
卵巢肿瘤; 圣愈汤; 增液汤; 联合化疗; Ki-67过表达
Keywords:
oophoroma;  ShengYuTang;  ZengYeTang;  combined chemotherapy;  Ki-67 over expression
分类号:
R713.6
文献标志码:
B
摘要:
目的:探讨圣愈汤合增液汤联合化疗治疗Ki-67(增殖细胞核抗原)过表达卵巢癌的临床疗效。方法:将68例卵巢癌患者随机分为对照组33例、观察组35例。对照组给予紫杉醇、卡铂(TC)联合化疗。观察组在对照组联合化疗的基础上加服中药圣愈汤合增液汤。比较2组临床疗效及不良反应发生情况。结果：病情总缓解率观察组为62.86%，对照组为60.61%，2组比较差异无统计学意义(P＞0.05)；生活质量改善率观察组为51.43%，对照组为24.24%，2组比较差异有统计学意义(P＜0.05)。血液系统和胃肠道不良反应发生率观察组低于对照组，2组比较差异有统计学意义(P＜0.05)。结论：圣愈汤合增液汤联合化疗能有效改善卵巢癌患者的生活质量，减少患者化疗后血液系统和消化系统不良反应的发生。
Abstract:
Objective: To discuss clinical effects of ShengYuTang, ZengYeTang combined with chemotherapy in the treatment for Ki-67 (proliferating cell nuclear antigen, PCNA) over expression of oophoroma. Methods: All 68 patients were randomized into 33 cases of the control group and 35 cases of the observation group. The patients in the control group were given paclitaxel, carboplatin (TC) and chemotherapy, while the ones in the observation group took ShengYuTang and ZengYeTang based on chemotherapy. Clinical effects and the incidences of adverse reaction of both groups were compared. Results: Total remission rate of disease conditions in the observation group was 62.86%, higher than 60.61% of the control group, and the difference had no statistical meaning (P＞0.05); improvement rate of life quality of the observation group was 51.43%, higher than 24.24% of the control group, and the difference had statistical meaning (P＜0.05). The observation group was lower than the control group signifi-cantly in adverse reaction incidences of blood system and gastrointestinal tract, and there was a significant difference (P＜0.05). Conclusion: ShengYuTang, ZengYeTang combined with chemotherapy could effectively improve quality of life of the oophoroma patients, reduce the incidences of adverse reaction in blood system and gastrointestinal tract of the patients after the chemotherapy

相似文献/References:

[1]王永,黄志惠,孙海清,等.圣愈汤加味治疗原发免疫性血小板减少症气不摄血证疗效观察[J].西部中医药,2025,38(06):137.[doi:10.12174/j.issn.2096-9600.2025.06.27]
　WANG Yong,HUANG Zhihui,SUN Haiqing,et al.Clinical Observation on Modified Shengyu Decoction in the Treatment of Primary Immune Thrombocytopenia of Qi Failing to Control Blood Pattern[J].Western Journal of Traditional Chinese Medicine,2025,38(04):137.[doi:10.12174/j.issn.2096-9600.2025.06.27]

备注/Memo

备注/Memo:
收稿日期：2017-10-20 作者简介：刘向华(1968—)，女，副主任医师。研究方向：妇科疾病的临床诊治。
更新日期/Last Update: 2018-04-15